



Merger Results in Leading Company for Oncolytic Adenoviruses for Cancer

HOUSTON, TX– October 23, 2012 – **DNAtrix, Inc.**, the Houston-based biotechnology company developing targeted adenovirus-based oncolytic virus products, announced today a merger with VectorLogics, Inc. (VLI), a company with a complementary intellectual property portfolio developing products for ovarian cancer. The merged company will retain the name DNAtrix and continue to develop its lead cancer product, DNX-2401, which is in clinical testing at the University of Texas M.D. Anderson Cancer Center for treating high grade brain tumors.

Dr. Imre Kovesdi, Ph.D., chief executive officer of VLI, and Dr. David T. Curiel, M.D., Ph.D., chief scientific officer and founder of VLI, will join the merged company as chief scientific officer and member of the Scientific Advisory Board, respectively. “We are extremely pleased to join forces with Drs. Curiel and Kovesdi in this important effort,” stated Frank Tufaro, Ph.D., chief executive officer of the merged company. “The merger makes strategic sense, and we are now a much stronger company in all respects.”

“As an inventor of VLI’s adenoviral technology,” stated Dr. Curiel. “I am very pleased to be able to work with the DNAtrix team in turning these discoveries into new cancer therapies. This is a win-win for both companies.”